Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Shares, with no par value
-
Shares outstanding
-
51M
-
Number of holders
-
11
-
Total 13F shares, excl. options
-
2.17M
-
Shares change
-
+341K
-
Total reported value, excl. options
-
$7.09M
-
Value change
-
+$1.12M
-
Number of buys
-
8
-
Number of sells
-
-4
-
Price
-
$3.28
Significant Holders of EUPRAXIA PHARMACEUTICALS INC. - Common Shares, with no par value (EPRX) as of Q1 2025
13 filings reported holding EPRX - EUPRAXIA PHARMACEUTICALS INC. - Common Shares, with no par value as of Q1 2025.
EUPRAXIA PHARMACEUTICALS INC. - Common Shares, with no par value (EPRX) has 11 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.17M shares
of 51M outstanding shares and own 4.25% of the company stock.
Largest 10 shareholders include SCOTIA CAPITAL INC. (1.55M shares), ROYAL BANK OF CANADA (343K shares), TD Waterhouse Canada Inc. (105K shares), BANK OF MONTREAL /CAN/ (52.3K shares), UBS Group AG (51.2K shares), GOLDMAN SACHS GROUP INC (34.5K shares), CITADEL ADVISORS LLC (12.1K shares), RAYMOND JAMES FINANCIAL INC (11.1K shares), JPMORGAN CHASE & CO (2.7K shares), and BANK OF AMERICA CORP /DE/ (2.5K shares).
This table shows the top 11 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.